The Rosen Law Firm Announces Investigation Of Securities Claims Against Pluristem Therapeutics, Inc. --- PSTI
The Rosen Law Firm announces that it is investigating potential securities claims against Pluristem Therapeutics, Inc. (NASDAQ: PSTI) resulting from allegations that the Company may have issued materially inaccurate statements to the investing public.
On May 9, 2012, Pluristem issued an announcement touting that its PLX Cells saved the life of a seven-year old girl. This announcement caused the Company’s stock to rise more than 13%. On September 19, 2012 the Company closed a public offering of 8 million shares of common stock - raising over $32 million. In connection with the offering, the Company issued a Prospectus that was filed with the SEC on September 14, 2012. The Prospectus mentioned the medical results for the seven-year old girl as an important clinical result supporting the effectiveness of PLX cells, omitting that she later died.
On November 8, 2012, Bloomberg published an article stating that on or before September 12, 2012 the seven-year old girl had died. This announcement caused the Company’s stock to fall, over 22%.
The Rosen Law Firm is investigating a securities class action lawsuit on behalf of Pluristem investors. If you purchased Pluristem securities in the public offering from Jefferies, Oppenheimer & Co., Needham & Co., or Maxim Group LLC, you may be able to recover your investment losses. Please visit the website at http://www.rosenlegal.com to join the prospective action. You may also contact Phillip Kim or Kevin Chan of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or kchan@rosenlegal.com.
The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Attorney Advertising. Prior results do not guarantee a similar outcome.Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
TheStreet Quant Ratings
TRY IT FREENew! $49.95/yr
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Product Features:
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Dividend Stock Advisor
TRY IT FREEJim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
